Leerink Partners Starts Crinetics (CRNX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Starts Crinetics (CRNX) at Overweight
August 13, 2018 4:06 AM EDTPiper Jaffray analyst Tyler Van Buren initiates coverage on Crinetics (NASDAQ: CRNX) with a Overweight rating and a price target of $40.00.
Van Buren believes CRN02481 has significant potential due to the lack of available treatment options and has a high level of... More
JPMorgan Starts Crinetics (CRNX) at Neutral
August 13, 2018 1:21 AM EDTJPMorgan analyst Jessica Fye initiates coverage on Crinetics (NASDAQ: CRNX) with a Neutral rating and a price target of $29.00.
Fye sees upside for the company over time as the company generates data supporting efficacy and safety in patients along with Phase 1 data for... More
